3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
72
Multiple Myeloma
70
Leukemia, Myeloid, Acute
70
Lymphoma, Large B-Cell, Diffuse
61
Lymphoma, Non-Hodgkin
58
Leukemia, Lymphocytic, Chronic, B-Cell
57
Lymphoma
56
Melanoma
52
Leukemia
52
Breast Neoplasms
49
Burkitt Lymphoma
48
Myelodysplastic Syndromes
44
Recurrence
41
Lymphoma, Follicular
41
Lymphoma, B-Cell
38
Lymphoma, Mantle-Cell
37
Ovarian Neoplasms
32
Neuroblastoma
32
Lymphoma, B-Cell, Marginal Zone
27
Sarcoma
26
Neoplasms
26
Carcinoma, Non-Small-Cell Lung
25
Hodgkin Disease
24
Neoplasm Metastasis
23
Triple Negative Breast Neoplasms
18
Carcinoma, Renal Cell
18
Neoplasms, Plasma Cell
17
Hematologic Neoplasms
17
Leukemia, Myelomonocytic, Chronic
16
Colorectal Neoplasms
16
Interventions
pembrolizumab
2
tislelizumab
1
Trastuzumab
1
Imatinib Mesylate
1
GSK-3326595
1
Cyclophosphamide
1
Blood Specimen Collection
1
BMS-906024
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Adenoid Cystic
×
Cyclophosphamide
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled